Seeking Alpha
 

United Therapeutics Corporation (UTHR)

- NASDAQ
  • Nov. 21, 2012, 5:16 PM
    The market is well-staged right now for gains in a number of sectors, says Sabrient Systems Chief Market Strategist David Brown. Health-care companies, the energy sector, housing businesses and airlines all can be purchased at reasonable prices now with solid growth prospects well into 2013. Despite market valuations being at reasonable levels relative to historic norms, there clearly are some bargains out there. His picks: United Therapeutics (UTHR), Marathon Petroleum (MPC), US Airways (LCC) and Delta (DAL).
    | 3 Comments
  • Nov. 1, 2012, 6:11 AM
    United Therapeutics (UTHR): Q3 EPS of $1.46 beats by $0.20. Revenue of $242.5M (+21% Y/Y) beats by $15M. (PR)
    | Comment!
  • Nov. 1, 2012, 12:05 AM
    Notable earnings before Thursday’s open: ABC, ABX, ADP, ALKS, APA, AVP, BCE, BYD, CI, CNSL, CTRX, CVC, DLPH, DX, EL, EPD, ESV, EXC, FIRE, GAS, GNC, GTLS, HEP, HSH, INCY, ITRI, IVZ, K, LLL, MPC, NGLS, NIHD, OCN, PEG, PFE, PXP, RDN, RGLD, SE, SIRI, SNE, SPR, TDC, TE, TEVA, UPL, UTHR, VNR, WNR, WPI, XOM, XYL
    | Comment!
  • Oct. 31, 2012, 5:30 PM
    Notable earnings before Thursday’s open: ABC, ABX, ADP, ALKS, APA, AVP, BCE, BYD, CI, CNSL, CTRX, CVC, DLPH, DX, EL, EPD, ESV, EXC, FIRE, GAS, GNC, GTLS, HEP, HSH, INCY, ITRI, IVZ, K, LLL, MPC, NGLS, NIHD, OCN, PEG, PFE, PXP, RDN, RGLD, SE, SIRI, SNE, SPR, TDC, TE, TEVA, UPL, UTHR, VNR, WNR, WPI, XOM, XYL
    | Comment!
  • Oct. 24, 2012, 12:45 PM
    Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%.
    | Comment!
  • Oct. 24, 2012, 9:10 AM
    Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
    Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%.
    | Comment!
  • Oct. 24, 2012, 8:25 AM
    United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR)
    | 1 Comment
  • Oct. 23, 2012, 5:40 PM
    After-hours top gainers, as of 5:15 p.m.: RFMD +12%; TWIN +9.2%; FB +8.2%; IDIX +6.5%; PNRA +6.4%.
    After-hours top losers: INVN -19.1%; TPX -18.4%; IRBT -15.2%; BWLD -10.2%; UTHR -9.9%.
    | 1 Comment
  • Jul. 26, 2012, 10:40 AM
    United Therapeutics (UTHR): Q2 EPS of $1.34 beats by $0.11. Revenue of $225.6M (+22.7% Y/Y) beats by $12.27M. (PR)
    | Comment!
  • Apr. 26, 2012, 11:59 AM
    United Therapeutics (UTHR): Q1 EPS of $1.32 beats by $0.32. Revenue of $204M (+25.7% Y/Y) in-line. (PR)
    | Comment!
  • Apr. 12, 2012, 11:33 AM
    United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a new price target of $48 from $65 by Leerink Swann, which cites generic risk to its treatment of pulmonary arterial hypertension. A recent survey by the firm says "most physicians believe that a minority of their patients are candidates for oral Remodulin."
    | Comment!
  • Mar. 20, 2012, 3:49 PM
    Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector, as it maintains a Buy rating on the biotech concern. Analysts with the firm expect Argus to hit its 2012 sales target, as they raise their price target on shares by $8 to $60.
    | Comment!
  • Mar. 15, 2012, 8:26 AM
    United Therapeutics (UTHR) files a patent infringement lawsuit against Novartis' (NVS) Sandoz unit over patents related to a pulmonary hypertension drug. Sandoz aims to sell a generic version of United's Remdoulin drug. NVS +0.2% premarket, UTHR inactive.
    | Comment!
  • Feb. 14, 2012, 7:37 AM
    United Therapeutics (UTHR): Q4 EPS of $0.77 misses by $0.08. Revenue of $195.2M (+19.2% Y/Y) misses by $9M. (PR)
    | Comment!
  • Feb. 14, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
Visit Seeking Alpha's
UTHR vs. ETF Alternatives
Company Description
United Therapeutics Corp is a biotechnology company. The Company is engaged in thedevelopment and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.